GLP-1 medications are effective for weight loss alongside diet and exercise changes in people with overweight or obesity
While demand for GLP-1 drugs appears to be accelerating, uncertainty around affordability, insurance coverage, and long-term access continues to shape whether interest translates into actual treatment
constipation, reflux, or intermittent nausea may continue Persistent or progressive symptoms rather than gradual improvement After month 3 Symptoms may remain mild or infrequent at a tolerated regimen New severe symptoms should not automatically be blamed on the medication The most important pattern is not simply "week 1 is bad and month 3 is good." A more accurate pattern is initiation, adaptation, possible symptom flare during dose escalation, and reassessment based on tolerability
This testing reveals whether your body has a naturally higher set-point for appetite or metabolic rate
The semaglutide sex drive women guide and related guides cover hormonal considerations for women on GLP-1 medications